Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells

Oligonucleotides

Volumn 16, Issue 3, 2006, Pages 263-274

  Priebsch, Axel ^a   Rompe, Franziska ^a   Tönnies, Holger ^b   Kowalski, Petra ^a   Surowiak, Pawel ^a   Stege, Alexandra ^a   Materna, Verena ^a   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VINCRISTINE;

ABCG2 GENE; ARTICLE; CARCINOMA CELL; CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; EXPRESSION VECTOR; GENE; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PLASMID VECTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; STOMACH CARCINOMA;

ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33751071871     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.16.263     Document Type: Article

References (39)

1. ALLIKMETS, R., SCHRIML, L.M., HUTCHINSON, A., ROMANO-SPICA, V., and DEAN, M. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339.
2. BIEDLER, J.L., and RIEHM, H. (1970). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174-1184.
3. BRUMMELKAMP, T.R., BERNARDS, R., and AGAMI, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
4. CHEN, Y.N., MICKLEY, L.A., SCHWARTZ, A.M., ACTON, E.M., HWANG, J.L., and FOJO, A.T. (1990). Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem. 265, 10073-10080.
5. DANTHINNE, X., and IMPERIALE, M.J. (2000). Production of first generation adenovirus vectors: A review. Gene Ther. 27, 1707-1714.
6. DIETEL, M., ARPS, H., LAGE, H., and NIENDORF, A. (1990). Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50, 6100-6106.
7. EE, P.L., HE, X., ROSS, D.D., and BECK, W.T. (2004). Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol. Cancer Ther. 3, 1577-1583.
8. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
9. GOTTESMAN, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
10. HARBORTH, J., ELBASHIR, S.M., BECHERT, K., TUSCHL, T., and WEBER, K. (2001). Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell Sci. 114, 4557-4565.
11. KELLEN, J. A. (2003). The reversal of multidrug resistance: An update. J. Exp. Ther. Oncol. 3, 5-13.
12. KELLNER, U., HUTCHINSON, L., SEIDEL, A., LAGE, H., DANKS, M.K., DIETEL, M., and KAUFMANN, S.C. (1997). Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int. J. Cancer 71, 817-824.
13. KOWALSKI, P., WICHERT, A., HOLM, P.S., DIETEL, M., and LAGE, H. (2001). Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 8, 185-192.
14. KOWALSKI, P., STEIN, U., SCHEFFER, G.L., and LAGE, H. (2002). Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 9, 579-586.
15. KOWALSKI, P., FARLEY, K.M., LAGE, H., and SCHNEIDER, E. (2004). Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. Anticancer Res. 24, 2231-2235.
16. KOWALSKI, P., SUROWIAK, P., and LAGE, H. (2005). Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol. Ther. 11, 508-522.
17. KRETSCHMER-KAZEMI FAR, R., and SCZAKIEL, G. (2003). The activity of siRNA in mammalian cells is related to structural target accessibility: A comparison with antisense oligonucleotides. Nucleic Acids Res. 31, 4417-4424.
18. LAGE, H. (2003a). ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents 22, 188-199.
19. LAGE, H. (2003b). Molecular analysis of therapy resistance in gastric cancer. Digest. Dis. 21, 326-338.
20. LAGE, H. (2005). Potential applications of RNA interference technology in the treatment of cancer. Future Oncol. 1, 103-113.
21. LAGE, H. (2006). MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 7, 813-821.
22. LAGE, H., and DIETEL, M. (2000). Effect of the breast cancer resistance protein on atypical multidrug resistance. Lancet Oncol. 1, 169-175.
23. LAGE, H., AKI-SENER, E., and YALCIN, I. (2006). High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs. Int. J. Cancer 119, 213-220.
24. LI, W.T., ZHOU, G.Y., SONG, X.R., CHI, W.L., REN, R.M., and WANG, X.W. (2005). Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 52, 219-224.
25. MEISTER, G., and TUSCHL, T. (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349.
26. MURATOVSKA, A., and ECCLES, M.R. (2004). Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558, 63-68.
27. NAKAGAWA, M., SCHNEIDER, E., DIXON, K.H., HORTON, J., KELLEY, K., MORROW, C., and COWAN, K.H. (1992). Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 52, 6175-6181.
28. NIETH, C., and LAGE, H. (2005). Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrp1 (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J. Chemother. 17, 215-223.
29. NIETH, C., PRIEBSCH, A., STEGE, A., and LAGE, H. (2003). Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545, 144-150.
30. ROBERT, J., and JARRY, C. (2003). Multidrug resistance reversal agents. J. Med. Chem. 46, 4805-4817.
31. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISTICA, D., WARREN, J.T., BOKESCH, H., KENNEY, S., and BOYD, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
32. STEGE, A., PRIEBSCH, A., NIETH, C., and LAGE, H. (2004). Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 11, 699-706.
33. STUART, D.D., KAO, G.Y., and ALLEN, T.M. (2000). A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 7, 466-475.
34. THOMAS, H., and COLEY, H.M. (2003). Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159-165.
35. TÖNNIES, H., NEUMANN, L.M., GRUNEBERG, B., and NEITZEL, H. (2003a). Characterization of a supernumerary ring chromosome 1 mosaicism in two cell systems by molecular cytogenetic techniques and review of the literature. Am. J. Med. Genet. A 121, 163-167.
36. TÖNNIES, H., POLAND, J., SINHA, P., and LAGE, H. (2003b). Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. Int. J. Cancer 103, 752-758.
37. WALTHER, W., STEIN, U., FICHTNER, I., MALCHEREK, L., LEMM, M., and SCHLAG, P.M. (2001). Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther. 8, 173-180.
38. WICHERT, A., STEGE, A., MIDORIKAWA, Y., HOLM, P.S., and LAGE, H. (2004). Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 23, 945-955.
39. ZHOU, S., SCHUETZ, J.D., BUNTING, K.D., COLAPIETRO, A.M., SAMPATH, J., MORRIS, J.J., LAGUTINA, I., GROSVELD, G.G., OSAWA, M., NAKAUCHI, H., and SORRENTINO, B.P. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034.